Ectonucleoside triphosphate diphosphohydrolase 6 expression in testis and testicular cancer and its implication in cisplatin resistance
Description
The development of resistance to cisplatin during treatment of testicular cancer constitutes a major obstacle to the cure of testicular cancer. To resolve its mechanism will provide useful information for making clinical decisions. We found 4 and 15 gene expressions were, respectively, up-regulated and down-regulated in cisplatin-resistant testicular cancer NEC-8/DDP cells compared with their parental NEC-8 cells (about 2.5-fold) using cDNA microarray analysis. After screening, we selected the ENTPD6 among these 19 genes. ENTPD6 was less expressed in cancerous region compared with that in non-cancerous lesion. In addition, ENTPD6 expression in seminoma was higher than that in other testicular tumors. ENTPD6 expression was involved in cellular sensitivity to cisplatin through an interaction with E-cadherin. ENTPD6 is a promising molecular biomarker of cisplatin resistance in testicular cancer, and also a novel therapeutical target modulating cisplatin resistance in testicular cancer.
Journal
-
- Oncology Reports
-
Oncology Reports 2011-04-20
Spandidos Publications
- Tweet
Keywords
- Male
- Reverse Transcriptase Polymerase Chain Reaction
- Antineoplastic Agents
- Cadherins
- Immunohistochemistry
- Gene Expression Regulation, Neoplastic
- Testicular Neoplasms
- Drug Resistance, Neoplasm
- Cell Line, Tumor
- Testis
- Biomarkers, Tumor
- Humans
- Cisplatin
- Pyrophosphatases
- Oligonucleotide Array Sequence Analysis
Details 詳細情報について
-
- CRID
- 1873679867590780416
-
- ISSN
- 17912431
- 1021335X
-
- PubMed
- 21519793
-
- Data Source
-
- OpenAIRE
